|
After a long day in surgery, it's BioTime. Actually, BioTime is more useful during a long day of surgery, with its water-based solutions to prevent massive blood loss after traumatic injury, preserve organs for transplant, and replace blood during such procedures as cardiac bypass. BioTime's Hextend product has received FDA approval to maintain blood volume during surgery. The firm is also developing PentaLyte, a version of the blood volume replacement product that metabolizes more quickly, and HetaCool, intended to replace blood volume in cryosurgery and preserve donated organs. Hospira distributes Hextend in the US and Canada, and CJ markets the drug in South Korea.
|
| | | Contact Information | |
Address: |
6121 Hollis St.
Emeryville, CA 94608
| | Phone: | 510-350-2940 | | Fax: | 510-350-2948 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1.50 M | | Revenue Growth (1 yr): | 43.70% | | Employees (2008): | 11 | | Employee Growth (1 yr): | 10.00% |
|
|
Key People
| | • |
Chairman:
Alfred D. Kingsley
| | • |
CEO and Director:
Michael D. West
| | • |
SVP and COO:
Robert W. Peabody
|
|
|
